Estrogen Receptor Agonist Market Outlook:
Estrogen Receptor Agonist Market size was valued at USD 3.32 billion in 2025 and is expected to reach USD 5.16 billion by 2035, expanding at around 4.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of estrogen receptor agonist is evaluated at USD 3.45 billion.
This rise in market demand is anticipated to be driven by the growing prevalence of cardiovascular disease. According to the World Health Organization, with about 17.9 million deaths per year, cardiovascular diseases (CVDs) are the major cause of death globally. Hence, in order to treat this the demand for different treatments is growing among which estrogen receptor agonist is most preferred. Additionally, it has been proven to be one of the safer treatments for cardiovascular diseases.
Furthermore, women who are in their post-menopausal period are usually given estrogen receptor agonist treatment since they suffer various consequences such as a decline in the concentration of sex steroid hormones in the blood owing to a decline of ovary function. By 2030, the post-menopausal women are projected to reach 1.2 billion, globally.
